| |
Untreated
|
14 Days Letrozole
|
90 Days Letrozole
|
|---|
|
Rank
|
Entrez ID
|
Gene symbol
|
Entrez ID
|
Gene symbol
|
Entrez ID
|
Gene symbol
|
|---|
|
1
|
28978
|
TMEM14A
|
79776
|
ZFHX4
|
1727
|
CYB5R3
|
|
2
|
1843
|
DUSP1
|
4701
|
NDUFA7
|
7083
|
TK1
|
|
3
|
51022
|
GLRX2
|
715
|
C1R
|
1292
|
COL6A2
|
|
4
|
1434
|
CSE1L
|
79818
|
ZNF552
|
857
|
CAV1
|
|
5
|
8522
|
GAS7
|
4046
|
LSP1
|
5437
|
POLR2H
|
|
6
|
51668
|
HSPB11
|
1727
|
CYB5R3
|
9833
|
MELK
|
|
7
|
10456
|
HAX1
|
357
|
SHROOM2
|
54861
|
SNRK
|
|
8
|
9902
|
MRC2
|
283298
|
OLFML1
|
4830
|
NME1
|
|
9
|
4706
|
NDUFAB1
|
23179
|
RGL1
|
231
|
AKR1B1
|
|
10
|
23560
|
GTPBP4
|
1809
|
DPYSL3
|
10418
|
SPON1
|
|
11
|
79633
|
FAT4
|
857
|
CAV1
|
2350
|
FOLR2
|
|
12
|
10418
|
SPON1
|
274
|
BIN1
|
10979
|
FERMT2
|
|
13
|
471
|
ATIC
|
79833
|
GEMIN6
|
11096
|
ADAMTS5
|
|
14
|
6403
|
SELP
|
11222
|
MRPL3
|
4638
|
MYLK
|
|
15
|
23421
|
ITGB3BP
|
23244
|
PDS5A
|
9448
|
MAP4K4
|
|
16
|
23452
|
ANGPTL2
|
6241
|
RRM2
|
54922
|
RASIP1
|
|
17
|
54861
|
SNRK
|
1289
|
COL5A1
|
6934
|
TCF7L2
|
|
18
|
2034
|
EPAS1
|
8434
|
RECK
|
4072
|
EPCAM
|
|
19
|
30008
|
EFEMP2
|
429
|
ASCL1
|
4701
|
NDUFA7
|
|
20
|
25999
|
CLIP3
|
3426
|
CFI
|
404672
|
GTF2H5
|
|
21
|
4311
|
MME
|
332
|
BIRC5
|
6241
|
RRM2
|
|
22
|
4747
|
NEFL
|
2
|
A2M
|
2192
|
FBLN1
|
|
23
|
1809
|
DPYSL3
|
10730
|
YME1L1
|
25959
|
KANK2
|
|
24
|
28998
|
MRPL13
|
11130
|
ZWINT
|
55651
|
NHP2
|
|
25
|
25959
|
KANK2
|
1292
|
COL6A2
|
5050
|
PAFAH1B3
|
- Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before, during, and after a course of neoadjuvant treatment with the drug letrozole. Bold font indicates genes that are also classified as hub-bottleneck genes.
